Featured Articles

  1. Partnering To Commercialize Radiopharmaceuticals 10/9/2025

    For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new products.

  2. Why I Love Working With Leaders Who Have 'Rounded Corners' 10/6/2025

    Life science leaders with 'rounded corners' lead to more enduring progress than razor-sharp perfection ever could, writes Tara Miller, founding partner at Artemis Factor.

  3. An Updated View Of The Federal Segment: Access Levers For Manufacturers 10/2/2025

    The third and final part of a series aimed at helping drug and device makers navigate the U.S. Veterans Affairs and Department of Defense health systems.

  4. Early-Stage Life Sciences Partnerships Raise Later-Stage Considerations 9/25/2025

    Emerging biotechs and their investors are exploring partnerships with drug companies at much earlier stages. Experts at Sidley Austin discuss key considerations for structuring partnership agreements.

  5. Pharma Direct-To-Patient 2.0: From Experiment To Imperative 9/23/2025

    Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access, according to Deepak Thomas and Sari Kaganoff.

  6. Strategic Approaches To Reducing Legal Spend Without Compromising Quality 9/19/2025

    Firm consolidation, thoughtful staffing, disciplined scope control, and performance accountability can save life sciences companies real money on legal expenses, writes Snell & Wilmer's April Wurster.

  7. RFK Jr. Wants Every American Wearing A Wearable. How Can Pharma Build A Business Around It? 9/16/2025

    The timing is now for pharma to be all-in on using wearables as their new business strategy, says Digital Medicine Society (DiMe) Director of Partnerships Smit Patel, PharmD.

  8. The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery 9/11/2025

    Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around. 

  9. How Biotech Leaders Keep Pace With The Next Wave Of Genetic Therapies 9/11/2025

    Epicrispr Biotechnologies CEO Amber Salzman, Ph.D. offers up four imperatives for industry leaders working to develop tomorrow's genetic therapies.

  10. The New FDA Era Of Radical Transparency And Pervasive Oversight 9/9/2025

    The first half of 2025 has been transformative for biopharmaceutical quality and regulatory affairs, with the FDA leading the charge with four significant changes. Curadian Group's David Grote discusses implications for all four.